Drug Trial Radar · NCT03521037
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
Last checked: Nov 20, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Feb 27, 2018
Primary completion
Sep 27, 2019
Study completion Feb 24, 2021
Sponsor
- Lead sponsor
- pharmaand GmbHIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1, open-label, parallel group, PK, safety and tolerability study in patients with an advanced solid tumor and either normal hepatic function (Group 1, n = 8) or moderate hepatic impairment (Group 2, n = 8) according to the NCI-ODWG criteria. Patients in Group 1 and Group 2 may be enrolled in parallel, with preferential enrollment of Group 2 patients before Group 1 patients. The study will consist of 2 parts: a single-dose PK part (Part I) and a continuous rucaparib treatment part (Part II).
Conditions
- Neoplasms
Interventions
Rucaparib camsylateDrug
In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma rucaparib concentration (Cmax)Time frame: day 1 to day 7
- Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration (AUC0-last)Time frame: day 1 to day 7
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
Biała Podlaska, Poland
Med Polonia Sp. z o.o.
Poznan, Poland
Zachodniopomorskie Centrum Onkologii w Szczecinie
Szczecin, Poland
BioVirtus Centrum Medyczne
Warsaw, Poland
Summit Clinical Research s.r.o.
Bratislava, Slovakia
Northern Centre for Cancer Care
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.